[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100124684":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":30,"locations":43,"responsibleParty":57,"collaborators":30,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":30,"acronym":30,"eligibilityCriteria":64,"healthyVolunteers":65,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":30,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":30,"overallStatus":78,"whyStopped":30,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":30,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Abbott","INDUSTRY",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"1","OTHER","Healthy volunteers, receiving daily dose of 80 mg ABT-072 or placebo, QD for 10 days; and on Study Day 11 receiving a single dose of 80 mg ABT-072 or placebo + 400 mg ketoconazole",[13,14,15],"Drug: ABT-072","Other: ketoconazole","Drug: Placebo",{"label":17,"type":10,"description":18,"interventionNames":19},"2","Healthy volunteers, receiving 160 mg ABT-072 or placebo, QD for 10 days.",[13,15],{"label":21,"type":10,"description":22,"interventionNames":23},"3","Healthy volunteers, receiving 320 mg ABT-072 or placebo, QD for 10 days.",[13,15],[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","ABT-072","Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.",[9,17,21],null,{"type":10,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"ketoconazole","Tablet, see Arm Description for intervention information.",[9],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"Placebo","Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.",[9,17,21],[40],{"name":41,"affiliation":5,"role":42},"Daniel Cohen, MD","STUDY_DIRECTOR",[44],{"facility":45,"status":30,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":30},"Abbott Clinical Pharmaceutical Research Unit","Waukegan","Illinois","60085","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-87.84479,42.36363,{"lat":55,"lon":54},{"type":30,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":58,"oldOrganization":5},"Daniel Cohen, MD\u002FStudy Medical Director","100124684","phase-1-a-study-in-healthy-adult-subjects-to-evaluate-the-safety-tolerability-and-pharmacokinetic-profiles-of-multiple-doses-of-abt-072-used-to-treat-hepatitis-c-100124684",false,"NCT00890318","A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C","Inclusion Criteria:\n\n* Main Selection Criteria for Healthy Volunteers:\n\n  * Subject has provided written consent.\n  * Subject is in general good health.\n  * If female, subject is postmenopausal for at least 2 years or surgically sterile.\n  * If female, subject is not pregnant and is not breast-feeding.\n  * Male or female between 18 and 55 years old, inclusive.\n  * If male, subject must be surgically sterile or practicing at least 1 method of birth control.\n  * Body Mass Index (BMI) is 18 to 29, inclusive.\n\nExclusion Criteria:\n\n* Use of medications including over the counter and vitamines.\n* Abuse of alcohol, drugs, or nicotine.\n* Current diseases or disorders.\n* History of cardiac disease.\n* If after consideration by the investigator, for any reason, that you are unsuitable to receive ABT-072.",true,"ALL","18 Years","55 Years",{"count":70,"type":71},32,"ACTUAL","INTERVENTIONAL",[74],"PHASE1","The purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of ABT-072 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of ketoconazole on steady state ABT-072 pharmacokinetics.",[77],"HCV Infection","COMPLETED","2010-10-19",{"date":81,"type":82},"2010-10-21","ESTIMATED",{"date":84,"type":30},"2009-04",{"name":5,"class":6},1]